Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Dutasteride and MK-2866 Interaction: Avoid | Peptide Database

Compound Profiles Dutasteride Dual 5-Alpha Reductase Inhibitor | Hair Loss & BPH Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, whi

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Dutasteride

Dual 5-Alpha Reductase Inhibitor | Hair Loss & BPH

Dutasteride competitively inhibits both the Type I and Type II isoforms of the enzyme 5-alpha reductase. Type II is the predominant isoform in the prostate and hair follicles, while Type I is found primarily in the skin, sebaceous glands, and liver.

MK-2866

Selective Androgen Receptor Modulator | Muscle Wasting Research

MK-2866 binds to the androgen receptor (AR) with high affinity and selectivity, functioning as a partial agonist in muscle and bone tissue. Upon binding, the MK-2866-AR complex undergoes a conformational change that promotes nuclear translocation and interaction with androgen response elements (AREs) on DNA, activating transcription of genes involved in protein synthesis, nitrogen retention, and myogenic differentiation.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Dutasteride with MK-2866?

Combining Dutasteride with MK-2866 is not recommended. Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Dutasteride and MK-2866 safe together?

This combination carries significant risk. Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Dutasteride and MK-2866?

Both Dutasteride and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 64% confidence and is inferred from pharmacological mechanism analysis.

How should I time Dutasteride and MK-2866?

Dutasteride has a half-life of ~5 weeks (extremely long; active metabolite accumulation over months) and MK-2866 has a half-life of ~24 hours. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the dose range for cognitive enhancement versus being too much?

The cognitive 'sweet spot' is 0.5-2 mg/kg body weight (roughly 35-140 mg for a 70 kg person). Doses above 2 mg/kg often shift from antioxidant to pro-oxidant effects, becoming counterproduc…

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

First-line pharmacotherapy for lifelong and acquired premature ejaculation. Clinically proven to increase intravaginal ejaculatory latency time (IELT), improve perceived control over ejaculation, and reduce personal distress related to PE. Improved ejaculatory control leads to greater sexual satisfaction for both the individual and their partner, as measured by validated patient-reported outcome instruments in clinical trials.

Source: peptide-db.com ↗

The Peptide Tier: Research Frontier

Standard supplements work through the gut. They’re absorbed, metabolised, and whatever reaches your mitochondria has been diluted along the way. Peptides bypass that. They’re injected directly into the bloodstream and reach mitochondria at therapeutic concentrations. Two peptides are specifically designed for mitochondrial function. Neither is FDA-approved. Both have stronger mechanistic data than most oral supplements.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

Anastrozole is administered orally as a tablet. It is well absorbed with approximately 83-85% bioavailability, and absorption is not significantly affected by food. The long half-life of 40-50 hours supports dosing every other day or every three days for most estrogen management protocols, rather than daily dosing which is primarily reserved for the medical breast cancer indication. On-cycle estrogen management (conservative) 0.25mg Every other day (EOD) or every 3 days (E3D) Oral On-cycle estrogen management (moderate) 0.5mg On-cycle estrogen management (aggressive) 1mg Every other day (EOD) TRT adjunct (low-dose) 0.125-0.25mg Twice weekly or as needed based on bloodwork Breast cancer treatment (medical) Once daily

Source: peptide-db.com ↗
Side effects

Common Side Effects

Decreased libido (reported in 3-5% of men; somewhat higher incidence than finasteride due to greater DHT suppression) Erectile dysfunction (reported in 3-5%; more frequently reported than with finasteride) Decreased ejaculate volume (reported in 1-2%) Gynecomastia or breast tenderness (reported in approximately 1-2%)

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides